– NORWAY, Oslo – Calluna Pharma AS, a clinical-stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, announced the appointments of Mark Gaffney as CEO and Mark Altmeyer as the Independent Chair of the Board of Directors.
About Mark Altmeyer
Mark Altmeyer, the newly appointed Independent Chair of the Calluna Board, brings extensive leadership experience, having served on the boards and as an advisor to several pharma and biotech companies. He is currently Chair of AM-Pharma and also serves on the boards of Novaremed, Merz Therapeutics, Aculys, and Alector, all focusing on CNS and neurological treatments. Previously, he was President and CEO of Arvelle Therapeutics, CCO at Axovant Sciences, and held senior roles at Otsuka America and Bristol-Myers Squibb.
Mark Altmeyer said: “It’s a great time to be joining Calluna Pharma’s Board and I look forward to working with Mark Gaffney as we steer company growth and the development of our programs. Working closely with Mark and his leadership team, we will continue to advance our mission to target the root causes of inflammation and fibrosis.”
Mark Altmeyer holds a BA in Economics from Middlebury College and an MBA from Harvard Business School.
About Mark Gaffney
Mark Gaffney brings over 20 years of experience in corporate strategy, business development, and operations in both private and public biotechnology companies, and will lead the team that defines and executes the corporate strategy, particularly as its lead program is on pace to complete its Phase 1 program later this year. Before Calluna, Gaffney was CEO of Oxular Limited, a company developing novel drug delivery and formulation technologies to treat retinal disorders, where he remains a strategic advisor and member of the Board. Before joining Oxular, he served as CBO and later as COO at Vedere Bio, a company focused on developing next-generation ocular gene therapies, which was acquired by Novartis in late 2020. Gaffney has held corporate development and operational positions at Cyclerion Therapeutics and Ironwood Pharmaceuticals
Mark Gaffney said: “It has been a rapid and impressive start to our journey as Calluna Pharma following joining forces of Oxitope Pharma and Arxx Therapeutics, two key players in the innate immunology space. I am delighted to join the team at such an exciting stage with Calluna’s lead candidate, CAL101, completing its Phase 1 program this year, and with the other programs in our pipeline demonstrating such promise. I look forward to working with Mark Altmeyer, the other members of our Board and the team as we continue to progress Calluna’s programs to make treatments for fibrotic and inflammatory diseases a reality.”
Mark Gaffney holds a degree in engineering from the University of Pennsylvania and a Juris Doctor degree from Boston University.
For more: https://www.callunapharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.